Improving Clinical Trials Through Inclusion, Access, and Engagement
Mariam F. Eskander, MD, MPH, and Coral O. Omene, MD, PhD, discuss potential strategies that teams can implement to ensure clinical trials are more representative of the general population.
Video Player is loading.
Mariam F. Eskander, MD, MPH, assistant professor of surgery and a gastrointestinal surgical oncologist at the Rutgers Cancer Institute, and Coral O. Omene, MD, PhD, an associate professor of medicine, breast medical oncologist, and program director for breast cancer disparities research at Rutgers Cancer Institute, discuss potential long-term, sustainable strategies that teams can implement to ensure clinical trials are more representative of the general population, and how that may differ between academic and community oncology settings.
Recent Videos
Real-World Bispecific Antibody Use Post-CAR T in DLBCL
Behind the Phase 3 3475A-D77 Trial of SC Pembrolizumab in NSCLC
Ferreyros on Biomarker Access and Physician Autonomy in Community Oncology
Site of Neuroendocrine Tumors Affects Outcomes With Cabozantinib
Exploring AFM13: Nieto on R/R Lymphoma Treatment Progress
Targeted Therapy Options Sometimes Underutilized in Metastatic CRC
Discussing ASCO Strategies to Help Address the Workforce Shortage
Pobel Translates PEACE-1 Trial Results Into Clinical Practice for mCSPC
Seymour on the BCL-2 Pathway and Novel Therapeutic Strategies in CLL
CBM588 With Cabozantinib/Nivolumab Shows Promise in Metastatic RCC
Related Content
